EU extends Tecfidera market exclusivity to Feb 2025

BIOGEN INC.

European Commission notified Biogen that Tecfidera's regulatory market protection extends to February 2, 2025.
The extension provides longer exclusivity for Biogen's multiple sclerosis drug, delaying generic competition.
Tecfidera contributed significant revenue; this decision supports Biogen's near-term cash flows.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.